Latest news with #ophthalmic
Associated Press
27-06-2025
- Business
- Associated Press
RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN ('RetinalGenix' or the 'Company'), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, has entered into an agreement with LabCorp, one of the nation's largest laboratory services organizations, to support the rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. This innovative program enables patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases. Through this collaboration, patients may visit any USA-based LabCorp location to have blood, tears, nasal secretions, and saliva collected and analyzed using proprietary algorithms developed by the RetinalGenix and DNA/RNA GPS analysis platform. These tests may correlate genetic and retinal biomarkers seeking to establish a new standard for early detection of a wide range of health conditions. Based on tests recommended by RetinalGenix, patients may elect to have their data analyzed using specific algorithms developed by RetinalGenix. This process is paired with DNA/RNA/GPS to correlate with current and future biomarkers found in the eye and the blood. Dr. Larry Perich, DO, Advisor for the DNA/RNA/GPS program, noted, 'As the database of disease-associated biomarkers expands, we expect the value of these platforms for diagnosing both ocular and systemic diseases continues to grow, promising improved outcomes and more accessible care.' Patients maintain full control of their health records, which remain anonymous and confidential. Appointments and test orders are managed via the RetinalGenix online platform, with results securely released to patients upon validation of payment at their chosen LabCorp center. Dr. Taimour Langaee, PhD, oversees the Company's DNA/GPS genotyping/sequencing data processing, genetic and pharmacogenomics data analyses, and clinical genetic association studies between eye diseases and genetic variations. Dr. Langaee said, 'I am excited that this creates great opportunities to further expand our knowledge about the important role of genetics and precision medicine in eye diseases, affecting millions of people and the potential to discover novel genetic variants and treatments.' High-resolution retinal imaging will be introduced by RetinalGenix as a value-added additional service at various locations in the near future. The integration of high-resolution imaging is expected to further boost diagnostic accuracy, allowing even general practitioners and standard eye clinics to assist in patient mass screening. These innovations are designed to make screening more accessible, cost-effective, and capable of detecting disease at earlier, more treatable stages. 'The cost of healthcare is enormous, and patient access is critical. This cost-effective methodology aims to reduce reliance on expensive diagnostic procedures such as MRIs, CT scans, PET Scans, echocardiograms to name a few, helping to alleviate the financial burden on both patients and the healthcare system. Equally important is avoiding the use of high-priced specialists to perform basic eye care services. The company is actively collaborating with regulators to establish CPT codes, which should lower healthcare costs and improve access to necessary evaluations. By doing so, the already overburdened patient assessment process can be streamlined,' stated Jerry Katzman, MD, RetinalGenix Technologies CEO. About RetinalGenix RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer's disease and Parkinson's disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer's disease/dementia. Safe Harbor Statement This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words 'could,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'may,' 'continue,' 'predict,' 'potential,' 'project' and similar expressions that are intended to identify forward-looking statements and include statements regarding reducing reliance on expensive diagnostic procedures with the Company's methodology, the planned rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, the program providing insights into both ocular and systemic diseases, correlating genetic and retinal biomarkers to seek to establish a new standard for the early detection of a wide range of health conditions, the value of platforms for diagnosing both ocular and systemic diseases continuing to grow, promising improved outcomes and more accessible care, the opportunities to further expand our knowledge about the important role of genetics and precision medicine in eye diseases and the potential to discover novel genetic variants and treatments, introducing high-resolution retinal imaging as an additional service in the near future, the integration of high-resolution imaging further boosting diagnostic accuracy, allowing even general practitioners and standard eye clinics to assist in patient mass screening, the innovations making screening more accessible, cost-effective, and capable of detecting disease at earlier, more treatable stages, establishing CPT codes to further lower healthcare costs and improve access to necessary evaluations and streamlining the patient assessment process. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to successfully complete research and further development and commercialization of Company products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company's products, the Company's ability to protect its intellectual property, and the risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and the Company's subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Media Contact: For further information, please contact: RetinalGenix Technologies Inc. Media and Investor Relations [email protected] (800) 331-5446
Globe and Mail
18-06-2025
- Business
- Globe and Mail
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ('Eyenovia' or the 'Company'), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capital strategy. Avenue Capital Group, now the Company's largest common stockholder, has agreed to amend Eyenovia's senior secured debt to further support the Company as it builds its HYPE treasury and reserve of the HYPE token. Pursuant to the terms of the amendment, the maturity date of the debt has been extended from November 1, 2025 to July 1, 2028 and its interest rate reduced from 12% to 8%. One half of the interest will be paid monthly in cash with the other half accrued and paid upon maturity. The Company will make interest-only payments during the initial 18 months of the extended term with equal principal and interest payments for the remaining 18 months. Michael Rowe, Chief Executive Officer of Eyenovia, stated, 'We are very grateful to Avenue Capital Group for their significant commitment and support of our innovative treasury strategy. We are pleased that they are positioned as a long-term partner, and we look forward to generating the sustained value creation that we anticipate from this initiative as well as the continued development and potential commercialization of our novel Optejet dispensing platform for the benefit of all shareholders.' Strategic Advisor Appointed for HYPE Treasury Strategy To support the Company's growing presence in the digital asset space, Eyenovia is also pleased to announce the appointment of Max Fiege as Strategic Advisor to support the HYPE Treasury strategy. He will support stakeholder education, ecosystem advocacy, treasury architecture, and risk oversight. Mr. Fiege currently serves as Principal at Merenti Capital GmbH, deploying proprietary capital across liquid and early-stage digital asset opportunities. With a background in blockchain growth and a track record of investing in innovative crypto projects, Mr. Fiege is well recognized for his expertise in navigating and shaping the digital finance landscape. 'It is a privilege to advise Eyenovia on the productive deployment of its HYPE treasury and I look forward to delegating Merenti Capital's own HYPE balance sheet to the Company's validator. Together, we will push the HYPE ecosystem forward,' said Mr. Fiege, Principal at Merenti Capital. 'Arguably no blockchain network has matched Hyperliquid's achievement: friction-free, transparent trading secured entirely on-chain. It is rare that a native token's incentives truly track the network's success. I believe HYPE is the best positioned digital asset for the future and that Eyenovia will effectively capture that value for shareholders.' About the HYPE Token HYPE is the native token of the Hyperliquid layer one blockchain (L1). HYPE is staked by, or delegated to, validators participating in the network's custom consensus algorithm, HyperBFT, which is optimized for order book logic and allows users to trade spot and futures markets in a non-custodial, on-chain fashion. Staked HYPE unlocks further utility in the form of trading fee discounts, with referral bonuses and builder-deployed markets (HIP-3) to be introduced in the future. Circulating HYPE is autonomously bought back and sequestered with trading fees accrued on the network's enshrined markets. As of June 2025, HYPE has become the 12th-largest cryptocurrency by market capitalization. About Eyenovia, Inc. Eyenovia, Inc. is a pioneering digital ophthalmic technology company and the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE. With this dual focus, Eyenovia continues to revolutionize topical eye treatment while providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility. Eyenovia is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. For more information, please visit Forward Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our platform technology, the viability of, and risks associated with, our new cryptocurrency treasury strategy, the clinical trials that may be necessary in connection with the clearance of the Optejet UFD, the timing for sales growth of our approved products. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds to maintain our business operations and to make payments on our debt obligations as and when necessary. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Yahoo
16-06-2025
- Business
- Yahoo
Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
MAHWAH, N.J., June 16, 2025 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC); compared to the active ingredient in Pataday®2 Once Daily Relief. According to Nielsen® syndicated data for the latest 52-week period ending May 17, 2025, the Pataday® Once Daily Relief (OTC) market3 achieved annual sales of approximately $50.0 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.2%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers." For product information and how to purchase, please visit: About Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (Glenmark_pharma). References 1 Glenmark's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) is only marketed for the indications listed in Glenmark's approved drug facts label. 2 This product is not manufactured or distributed by Alcon Laboratories, Inc., distributor of Pataday® Once Daily Relief, and/or Novartis AG, owner of the registered trademark Pataday®, respectively. [Neither Alcon nor Novartis make or license Glenmark's product.] 3 Market includes brand and all available therapeutic equivalents. Note: Nielsen syndicated data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications. *Nielsen® NIQ Discover; Syndicated Data for Period Ending May 17, 2025 Logo: View original content: SOURCE Glenmark Pharmaceuticals Ltd Sign in to access your portfolio
Reuters
30-05-2025
- Business
- Reuters
Essilorluxottica to buy Optegra eyecare clinics
MILAN, May 30 (Reuters) - Essilorluxottica ( opens new tab has entered an agreement to buy Optegra ophthalmic clinics from MidEuropa, as the Franco-Italian eyewear group aims to expand in the medical technology industry, the companies said on Friday. Financial details of the transaction, which is expected to close later this year, were not disclosed. The Optegra group operates a network of over 70 eye hospitals and diagnostic facilities in the UK, Czech Republic, Poland, Slovakia and the Netherlands under the Optegra, Lexum and Iris brands. It serves both publicly reimbursed and private-pay patients, providing treatments and vision correction procedures such as cataract surgery, age-related macular degeneration and glaucoma treatments, refractive lens replacement and laser eye surgery. "With the acquisition of Optegra, we are stepping into a new frontier – one where comprehensive eyecare, advanced diagnostics, therapeutic interventions and surgical treatments come together in one seamless platform", Essilorluxottica CEO Francesco Milleri and deputy CEO Paul du Saillant said in a statement. Essilorluxottica was advised by Rothschild for the transaction. It is aiming to expand beyond its traditional lenses and sunglasses products, into complementary sectors characterised by a strong technological component, such as Ray-Ban Meta smart glasses or hearing aids applied to glasses.
Yahoo
26-05-2025
- Business
- Yahoo
U.S. Ophthalmic Photocoagulator Growth Trends and Forecasts 2025-2032 - Market Expands Amid Surge in Diabetic Retinopathy Cases
Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like Lumenis Be Ltd. and IRIDEX are innovating to meet growing demands. Recent FDA approvals highlight ongoing advancements in portable laser technologies. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "U.S. Ophthalmic Photocoagulator Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Country: (U.S.)" report has been added to U.S. ophthalmic photocoagulator market is poised for substantial growth, with projections indicating a rise from US$ 52.62 million in 2025 to US$ 74.3 million by 2032. This expansion reflects a compound annual growth rate (CAGR) of 5.05% over the forecast period from 2025 to 2032. With a growing elderly population and rising prevalence of eye-related conditions such as diabetic retinopathy and macular degeneration, the demand for advanced ophthalmic laser treatments is accelerating across the photocoagulators are precision laser systems designed to treat retinal diseases by coagulating blood vessels in the retina. These devices play a critical role in treating vision-threatening conditions such as diabetic retinopathy, age-related macular degeneration, and macular edema. As technological advancements continue to reshape the ophthalmology Analysis, there is a clear shift toward minimally invasive and highly precise treatment the adoption of multicolor scan laser photocoagulators is on the rise due to their ability to deliver multiple wavelengths, enabling targeted treatment across various retinal layers. These systems offer improved patient outcomes and reduced side effects, making them a preferred choice for eye care professionals and patients DriversA key factor fueling market expansion is the increasing prevalence of diabetes and associated retinal complications. Diabetic retinopathy remains a leading cause of vision impairment among adults in the United States. With the diabetic population continuing to rise, there is a parallel increase in the demand for effective retinal treatments, such as laser advancements in multicolor and wavelength laser technologies are transforming treatment possibilities. New-generation lasers offer ophthalmologists improved precision, flexibility, and the ability to tailor treatments based on individual patient conditions. These capabilities are particularly beneficial in outpatient settings, contributing to the growing popularity of these systems in ambulatory surgical centers and ophthalmic OpportunityThe emergence of portable and compact laser systems presents a lucrative opportunity for market players. As the healthcare system shifts toward outpatient care and point-of-service treatment, portable photocoagulators offer greater flexibility and access, particularly in smaller clinics and rural settings. These devices are easier to operate, more cost-effective, and suitable for a wider range of treatment significant opportunity lies in the increasing number of outpatient laser procedures. These treatments provide advantages such as faster recovery, reduced costs, and enhanced patient convenience. The transition from hospital-based to outpatient treatment modalities is expected to expand the customer base for photocoagulator manufacturers, especially those that offer scalable, user-friendly ChallengesDespite favorable growth conditions, the market is not without challenges. One of the primary restraints is limited reimbursement for photocoagulation procedures. Stringent insurance policies and high out-of-pocket costs may deter patients from pursuing necessary treatment or adhering to follow-up schedules. Furthermore, for healthcare providers, limited reimbursement often affects the adoption of advanced laser systems, especially in budget-constrained challenge stems from competition with alternative treatments. Anti-VEGF injections and newer pharmacological therapies are increasingly preferred for conditions like age-related macular degeneration and diabetic macular edema. These alternatives offer non-laser treatment options that are less invasive and often more comfortable for patients, posing a potential threat to the uptake of traditional laser-based AnalysisThe U.S. ophthalmic photocoagulator market benefits significantly from a well-established healthcare infrastructure and a high level of awareness regarding eye health. Increasing investments in ophthalmology research, expanding healthcare access through outpatient services, and a growing aging population make the U.S. a strong growth engine for the widespread adoption of advanced diagnostic and therapeutic solutions, the country is experiencing a shift toward personalized and preventive eye care. This evolution is driving the demand for devices that offer precise, customizable treatments - a trend well-supported by the introduction of multicolor scan lasers and minimally invasive Landscape Companies are focused on expanding their product portfolios, enhancing treatment precision, and increasing accessibility to advanced photocoagulation devices across healthcare settings. Key Players Lumenis Be Ltd. IRIDEX Corporation Alcon Inc. Quantel Medical (Lumibird Medical) NIDEK CO., LTD. Johnson & Johnson Vision Care, Inc. TOPCON CORPORATION Bausch & Lomb Incorporated Meridian Medical Group Lab Medica Systems Pvt. Ltd Norlase OD-OS Zeiss A.R.C. Laser GmbH MEDA Co., Ltd. Market SegmentationBy Wavelength: Yellow Scan Laser Photocoagulator Red Scan Laser Photocoagulator Green Scan Laser Photocoagulator Multicolor Scan Laser Photocoagulator By Application: Macular Edema Age-related Macular Degeneration Diabetic Retinopathy Glaucoma Others By End User: Hospitals Ophthalmic Clinics Ambulatory Surgical Centers Others For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
